StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) in a research note issued on Wednesday. The brokerage set a “hold” rating on the medical research company’s stock.
Accelerate Diagnostics Trading Down 6.8 %
Shares of NASDAQ AXDX opened at $1.50 on Wednesday. Accelerate Diagnostics has a twelve month low of $0.73 and a twelve month high of $7.00. The firm has a 50-day moving average of $1.49 and a two-hundred day moving average of $1.20. The company has a market capitalization of $33.08 million, a price-to-earnings ratio of -0.37 and a beta of 0.62.
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last released its earnings results on Thursday, August 8th. The medical research company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. The business had revenue of $2.99 million for the quarter, compared to analyst estimates of $3.00 million. As a group, research analysts predict that Accelerate Diagnostics will post -2.14 earnings per share for the current year.
Hedge Funds Weigh In On Accelerate Diagnostics
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
See Also
- Five stocks we like better than Accelerate Diagnostics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 3 Leveraged ETFs to Multiply Returns
- Profitably Trade Stocks at 52-Week Highs
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- Investing In Preferred Stock vs. Common Stock
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.